Alx Oncology Holdings (ALXO) Research & Development (2019 - 2026)
Alx Oncology Holdings recorded quarterly Research & Development of $13.6 million in Q1 2026, down 22.89% quarter-over-quarter from $17.6 million in Q4 2025, and down 43.04% year-over-year from $23.9 million in Q1 2025.
Alx Oncology Holdings' Research & Development history runs 8 years deep, the most recent figure standing at $13.6 million for Q1 2026.
- In Q1 2026, Research & Development fell 43.04% year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $66.7 million (down 38.54% YoY), while the FY2025 annual figure was $77.0 million, down 33.84% from the prior year.
- Research & Development came in at $13.6 million for Q1 2026 at Alx Oncology Holdings, down from $17.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $45.8 million in Q3 2023 to a low of $13.6 million in Q1 2026.
- A 5-year average of $26.3 million and a median of $25.2 million in 2022 frame the typical range for Research & Development.
- Across the five-year window, Research & Development soared 138.54% in 2022 and sank 47.99% in 2025, its largest moves.
- Alx Oncology Holdings' Research & Development stood at $25.2 million in 2022, then jumped by 65.83% to $41.8 million in 2023, then sank by 43.68% to $23.5 million in 2024, then declined by 25.02% to $17.6 million in 2025, then declined by 22.89% to $13.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $13.6 million, $17.6 million, and $17.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | 13.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.61 Mn |
| Dec 31, 2025 | 17.65 Mn |
| Sep 30, 2025 | 17.44 Mn |
| Jun 30, 2025 | 18.02 Mn |
| Mar 31, 2025 | 23.89 Mn |
| Dec 31, 2024 | 23.53 Mn |
| Sep 30, 2024 | 26.47 Mn |
| Jun 30, 2024 | 34.65 Mn |
| Mar 31, 2024 | 31.72 Mn |
| Dec 31, 2023 | 41.78 Mn |
| Sep 30, 2023 | 45.77 Mn |
| Jun 30, 2023 | 29.48 Mn |
| Mar 31, 2023 | 24.76 Mn |
| Dec 31, 2022 | 25.20 Mn |
| Sep 30, 2022 | 29.38 Mn |
| Jun 30, 2022 | 26.75 Mn |
| Mar 31, 2022 | 17.07 Mn |
| Dec 31, 2021 | 20.89 Mn |
| Sep 30, 2021 | 18.21 Mn |
| Jun 30, 2021 | 11.21 Mn |
| Mar 31, 2021 | 9.85 Mn |
| Dec 31, 2020 | 12.14 Mn |
| Sep 30, 2020 | 5.33 Mn |
| Jun 30, 2020 | 7.66 Mn |
| Mar 31, 2020 | 3.83 Mn |
| Dec 31, 2019 | 6.74 Mn |
| Sep 30, 2019 | 2.21 Mn |
| Jun 30, 2019 | 3.63 Mn |